论文部分内容阅读
目的了解本院2013年-2016年血流感染非产超广谱β-内酰胺酶大肠埃希菌(非ESBLs-EC)和产超广谱β-内酰胺酶大肠埃希菌(ESBLs-EC)的科室分布情况及耐药情况。方法选择2013年-2016年临床微生物实验室分离出的非ESBLs-EC和ESBLs-EC,排除污染、并确诊为血流感染的患者,使用WHONET 5.6进行科室分布情况和耐药性统计分析。结果 2013年-2016年共检出非ESBLs-EC 275株,ESBLs-EC 221株。ESBLs-EC检出前5位的科室依次为肝胆外科、ICU、泌尿外科、感染科、肿瘤科。非ESBLs-EC检出前5位的科室依次是肝胆外科、感染科、ICU、呼吸科、肿瘤科。非ESBLs-EC对常用抗菌药物总体敏感性较高,ESBLs-EC对头孢菌素、喹诺酮类、氨基糖苷类抗菌药物耐药率较高。结论 ESBLs-EC对抗菌药物耐药率较高。治疗ESBLs-EC血流感染的患者可选含酶抑制剂的复合制剂或碳青霉烯类抗菌药物。
Objective To understand the prevalence of ESBLs-producing Escherichia coli (ESBLs-EC) and ESBLs-producing Escherichia coli (ESBLs-EC) ) Department of the distribution and drug resistance. Methods Non-ESBLs-EC and ESBLs-EC isolated from clinical microbiology laboratories between 2013 and 2016 were selected to exclude contamination and diagnosed as bloodstream infections. The distribution of the departments and statistical analysis of drug resistance were performed using WHONET 5.6. Results A total of 275 non-ESBLs-EC strains and 221 ESBLs-EC strains were detected in 2013-2016. The top 5 departments of ESBLs-EC were hepatobiliary surgery, ICU, urology, infection and oncology. The top 5 non-ESBLs-EC departments were hepatobiliary surgery, infection department, ICU, respiratory department and oncology department. Non-ESBLs-EC is generally sensitive to commonly used antimicrobial agents. ESBLs-EC has a higher resistance to cephalosporins, quinolones and aminoglycosides. Conclusion ESBLs-EC has high resistance to antibiotics. Patients with ESBLs-EC bloodstream infections may be given an enzyme inhibitor-containing combination or carbapenem-based antimicrobials.